Dr. Jodi L. Skiles
Claim this profileRiley Hospital for Children
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
6 reported clinical trials
10 drugs studied
Area of expertise
1Leukemia
CD19 positive
CD22 positive
Stage II
2Lymphoblastic Leukemia-Lymphoma
CD19 positive
Stage II
Stage I
Affiliated Hospitals
Clinical Trials Jodi L. Skiles is currently running
Non-TBI Conditioning
for HCT in Acute Lymphoblastic Leukemia
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regimen as part of the treatment cohort of the study. Subjects who are pre-HCT NGS-MRD positive will be treated as per treating center standard and will be followed in an observational cohort (HCT center standard of care).
Recruiting1 award Phase 2
CAR T-Cell Therapy
for Leukemia and Lymphoma
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cells, and the phase 2 part of the study will determine how effective this CAR T cell therapy is. Both patients who have never had prior CAR T cell therapy and those who have had prior CAR T cell therapy may be eligible to participate in this study.
Recruiting1 award Phase 1 & 215 criteria
More about Jodi L. Skiles
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jodi L. Skiles has experience with
- Melphalan
- Fludarabine
- Alemtuzumab
- Tisagenlecleucel
- Matched Unrelated Donor Hematopoietic Cell Transplantation (MUD-HCT)
- Haploidentical Hematopoietic Cell Transplantation (haploHCT)
Breakdown of trials Jodi L. Skiles has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jodi L. Skiles specialize in?
Jodi L. Skiles focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved CD19 positive patients, or patients who are CD22 positive.
Is Jodi L. Skiles currently recruiting for clinical trials?
Yes, Jodi L. Skiles is currently recruiting for 4 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Jodi L. Skiles has studied deeply?
Yes, Jodi L. Skiles has studied treatments such as Melphalan, Fludarabine, Alemtuzumab.
What is the best way to schedule an appointment with Jodi L. Skiles?
Apply for one of the trials that Jodi L. Skiles is conducting.
What is the office address of Jodi L. Skiles?
The office of Jodi L. Skiles is located at: Riley Hospital for Children, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Riley Hospital for Children.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.